Digital Therapeutics provider Mahana Therapeutics has entered a multi-million dollar distribution and marketing agreement. Bayer's consumer health division will market Mahana's portfolio of prescription digital therapeutics. This represents a landmark investment by a major drug company into the growing field of digital therapeutics: Software-based medical treatments.

Under the terms of the agreement, Bayer will use its global distribution network and marketing capabilities to facilitate the expansion of Mahana’s prescription digital therapeutics for the treatment of chronic conditions globally. The company’s first treatment, Mahana IBS, was approved by the FDA for the treatment of irritable bowel syndrome in 2021. 

The deal supports Bayer's recent launch of a business unit to develop digital health products, allowing consumers to better manage their health through personalized insights and digital tools.